FDA Worried Jakafi May Have Cancer, Heart Risks Similar to Xeljanz
The FDA has delayed an expanded approval for the drug Jakafi, potentially due to concerns over heart and cancer risks linked to Pfizer's Xeljanz, a similar drug.
Tag Archives: Heart Attacks
-
-
Speculation Mounts for Potential FDA Panel Review of Health Risks from Xeljanz, Other JAK Inhibitors
Some believe the FDA is preparing to review the risks and benefits of Xeljanz and similar drugs given recent cancer and heart concerns.
-
Investigation of Xeljanz Cancer and Heart Risks Launched in Canada
Growing concerns have led to Health Canada announcing a Xeljanz safety review, to determine whether more warnings or actions are needed following studies suggesting the ulcerative colitis drug could increase…
-
Xeljanz Cancer Warnings Leave More Questions Than Answers
New Xeljanz research links the drug to cancer risks, but has not yet led to a warning for users as to which types of cancer they may face.
-
Pfizer Files Lawsuit Over Xeljanz Generic Application
Pfizer filed a patent lawsuit over an alleged attempt to create a generic version of Xeljanz shortly after the FDA announced new concerns about the drug's safety.
-
Xeljanz Problems Highlighted in Study Data May Lead to New FDA Restrictions: Report
The FDA is weighing new restrictions on Xeljanz, following clinical trial data linking the drug to an increased risk of heart problems and cancer, according to a new report.
-
Xeljanz Side Effects May Increase Risk of Cancer, Serious Heart Problems: FDA Alert
A new FDA warning indicates Xeljanz side effects may increase the risk of heart problems, including heart attacks, and cancer in patients over 50.
-
Actemra Study Looking At Use As Treatment for Systemic Sclerosis
Actemra is being tested in an ongoing clinical trial as a potential treatment for systemic sclerosis, despite growing concerns linking the drug to heart attacks, strokes, and deaths.
-
Testosterone Gel Side Effects Do Not Thicken Artery Walls Or Improve Quality of Life: Study
A new study's findings indicate that while testosterone gels do not thicken artery walls, they also do not appear to significantly improve quality of life for older men.
-
AbbVie Seeks Dismissal of Androgel Lawsuits as Bellwether Selections Approach
AbbVie is pushing to have a number of cases dismissed for not having submitted complete Plaintiff Fact Sheets, but plaintiffs' attorneys say the company is trying to game the system…